Biogen (NASDAQ:BIIB) Upgraded at UBS Group

UBS Group upgraded shares of Biogen (NASDAQ:BIIB) from a neutral rating to a buy rating in a report published on Wednesday morning, Marketbeat reports. They currently have $225.00 price objective on the biotechnology company’s stock, up from their prior price objective of $185.00.

BIIB has been the subject of several other reports. Wedbush lifted their price target on shares of Biogen from $187.00 to $191.00 and gave the company a “neutral” rating in a report on Wednesday, April 1st. Oppenheimer lifted their price target on shares of Biogen from $250.00 to $275.00 and gave the company an “outperform” rating in a report on Wednesday, April 1st. Canaccord Genuity Group lifted their price target on shares of Biogen from $230.00 to $245.00 and gave the company a “buy” rating in a report on Wednesday, April 1st. Tudor Pickering set a $201.00 price target on shares of Biogen in a report on Monday, February 9th. Finally, Wells Fargo & Company lifted their price target on shares of Biogen from $190.00 to $200.00 and gave the company an “equal weight” rating in a report on Sunday, February 8th. Fourteen equities research analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $211.31.

Biogen Trading Down 1.9%

NASDAQ BIIB opened at $184.38 on Wednesday. Biogen has a one year low of $115.25 and a one year high of $202.41. The company has a 50-day simple moving average of $185.13 and a 200-day simple moving average of $175.03. The company has a debt-to-equity ratio of 0.34, a quick ratio of 2.03 and a current ratio of 2.68. The firm has a market capitalization of $27.06 billion, a PE ratio of 20.93, a price-to-earnings-growth ratio of 2.51 and a beta of 0.16.

Biogen (NASDAQ:BIIB) last posted its quarterly earnings results on Friday, February 6th. The biotechnology company reported $1.99 EPS for the quarter, beating the consensus estimate of $1.61 by $0.38. Biogen had a net margin of 13.07% and a return on equity of 12.64%. The business had revenue of $2.28 billion during the quarter, compared to analyst estimates of $2.21 billion. During the same period in the previous year, the business posted $3.44 EPS. The company’s quarterly revenue was down 7.2% on a year-over-year basis. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. On average, equities analysts forecast that Biogen will post 15.77 earnings per share for the current year.

Insiders Place Their Bets

In related news, insider Priya Singhal sold 2,660 shares of Biogen stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $199.83, for a total value of $531,547.80. Following the sale, the insider directly owned 8,043 shares in the company, valued at $1,607,232.69. This trade represents a 24.85% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.18% of the stock is currently owned by corporate insiders.

Institutional Trading of Biogen

Several hedge funds have recently bought and sold shares of BIIB. Empowered Funds LLC lifted its position in Biogen by 64.9% in the 1st quarter. Empowered Funds LLC now owns 7,054 shares of the biotechnology company’s stock valued at $965,000 after purchasing an additional 2,777 shares during the last quarter. Focus Partners Wealth lifted its position in Biogen by 172.2% in the 1st quarter. Focus Partners Wealth now owns 10,173 shares of the biotechnology company’s stock valued at $1,392,000 after purchasing an additional 6,436 shares during the last quarter. Sivia Capital Partners LLC bought a new stake in shares of Biogen during the 2nd quarter worth about $216,000. Cerity Partners LLC raised its position in shares of Biogen by 15.3% during the 2nd quarter. Cerity Partners LLC now owns 46,552 shares of the biotechnology company’s stock worth $5,847,000 after buying an additional 6,184 shares in the last quarter. Finally, NewEdge Advisors LLC raised its position in shares of Biogen by 13.4% during the 2nd quarter. NewEdge Advisors LLC now owns 2,673 shares of the biotechnology company’s stock worth $336,000 after buying an additional 316 shares in the last quarter. 87.93% of the stock is currently owned by institutional investors.

More Biogen News

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Biogen struck a China deal to develop felzartamab as a domestically produced anti‑CD38 therapy for multiple myeloma — this expands its China footprint and could open a meaningful growth market. Biogen seeks Darzalex rivalry in China for multiple myeloma with felzartamab deal
• Positive Sentiment: UBS upgraded Biogen, and JPMorgan raised its price target to $185 (still a Neutral rating) — these moves provide some analyst validation for the story but stop short of a full buy case. UBS upgrades Biogen (BIIB) JPMorgan raises price target
• Neutral Sentiment: Q1 earnings preview pieces highlight that new products (Skyclarys, Zurzuvae) are driving growth but legacy MS sales face competitive pressure — outcome of Q1 will be a key catalyst and remains uncertain. Biogen Q1 Earnings: Can New Launches Offset Declining MS Franchise?
• Neutral Sentiment: Rothschild & Co Redburn issued EPS estimates and raised its price target to $180 while maintaining a Neutral rating — adds supply of modeled forecasts but not a bullish call. Rothschild & Co Redburn estimates and target
• Negative Sentiment: Short interest rose to ~4.41M shares as of April 15 (+15.4% vs. March 31), representing about 3.0% of float and a short‑interest ratio ~3.1 days — higher shorting can amplify downward pressure around weak news. (Note: an April 24 data point showing zero shares appears to be a reporting anomaly.)
• Negative Sentiment: Wolfe Research trimmed Q1 and Q2 EPS estimates (and trimmed Q2 guidance), signaling risk to near‑term earnings expectations and likely contributing to negative trading sentiment.

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.